查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1802968

2032 年人工智慧老年保護劑市場預測：按治療領域、技術、應用、最終用戶和地區分類的全球分析

AI Geroprotector Discovery Market Forecasts to 2032 - Global Analysis By Therapeutic Area, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球人工智慧老年保護器市場規模預計在 2025 年將達到 3.16 億美元，到 2032 年將達到 16.28 億美元，預測期內的複合年成長率為 26.4%。

AI 抗衰老藥物研發是指應用人工智慧和機器學習來識別、篩檢和最佳化能夠減緩、預防或逆轉老化相關過程的化合物和干涉措施。透過分析海量生物資料集，AI 可以快速預測潛在的抗衰老化合物，減少藥物開發中的試驗，並加速老化機制的精準標靶化。

全球老齡人口正在增加

全球老年人口的成長是人工智慧老年保護劑研發市場的主要驅動力。老年人口中與老齡化相關的疾病的盛行率不斷上升，從而擴大了對針對老齡化生物學機制的創新治療性介入的需求。此外，這種人口結構的變化給醫療保健系統帶來了巨大壓力，迫切需要有效且具預防性的抗衰老解決方案。因此，老齡化人口的成長直接推動了對人工智慧主導的老年保護劑研發的投資和研究，這些產品有望延長健康壽命，並減輕與老齡化相關疾病相關的經濟負擔。

技術基礎設施的初始資本投入高

開發和應用用於藥物研發的人工智慧演算法需要高效能運算 (HPC) 系統、海量資料儲存解決方案以及專用軟體，而所有這些成本都高得令人望而卻步。招募一批由資料科學家、計算生物學家和人工智慧專家組成的高技能人才隊伍，將進一步增加營運成本。如此高的經濟障礙可能會扼殺創新，有效強化資金雄厚的現有企業的市場准入，並限制小型企業的參與。

個性化抗衰老方案的開發

利用人工智慧演算法，我們可以分析多組體學數據、生活方式因素和臨床病史，從而識別患者特異性的衰老生物標記物，並預測個體對潛在抗衰老藥物的反應。這項技術有助於開發高度客製化的治療方法，以最大限度地提高療效並最大限度地減少副作用。此外，這種個人化方法還可以在臨床試驗中對患者群體進行分層，從而最佳化研究設計並加快新型靶向抗衰老化合物的核准進程。

黑箱問題與人工智慧預測的可解釋性

如果人工智慧系統產生潛在的抗衰老候選藥物，卻無法提供清晰、可解釋的生物學基礎見解，就會造成重大障礙。 FDA 和 EMA 等監管機構要求全面了解藥物的作用機制才能批准。這種不透明性可能會削弱臨床醫生和研究人員的信心，延遲臨床應用，並限制人工智慧衍生的發現廣泛融入主流治療開發平臺。

COVID-19的影響：

新冠疫情對人工智慧抗衰老藥物研發市場產生了雙重影響。最初，它擾亂了研究活動和供應鏈，導致與新冠疫情無關的計劃暫時延遲。然而，它隨後又成為重要的催化劑，凸顯了先進計算方法在快速藥物研發和再利用中的關鍵作用。疫情凸顯了老齡化人口對新型病原體的脆弱性，並強調了延長健康壽命研究的重要性。這導致投資者對人工智慧驅動的生物技術平台的興趣和資金投入增加，最終對市場成長產生了長期的正面影響。

機器學習 (ML) 將成為預測期內最大的細分市場

機器學習 (ML) 領域預計將在預測期內佔據最大的市場佔有率，這得益於其在海量生物資料集中識別複雜非線性模式方面無與倫比的能力。機器學習演算法，尤其是深度學習網路，非常擅長處理高通量篩檢資料、基因組序列和蛋白質體學譜，從而預測新分子的生殖保護作用和毒性。它們能夠不斷從新數據中學習和改進，這對於目標識別、先導藥物最適化和生物標記發現至關重要。這種多功能性及其在其他藥物發現領域已證實的有效性，鞏固了機器學習作為最大細分市場的地位。

預計腫瘤學在預測期內將以最高的複合年成長率成長

由於老化與致癌作用密切相關，腫瘤學領域預計將在預測期內呈現最高成長率。老齡化是癌症的主要風險因素，因為細胞損傷和老化的累積為腫瘤的形成創造了有利環境。許多抗衰老藥物透過選擇性清除癌前衰老細胞而展現出強大的抗癌活性。老化社會中癌症的高發性為能夠同時針對基本老化過程和癌症發展的人工智慧發現療法提供了清晰的臨床路徑和巨大的潛在市場，從而推動了該領域的成長。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率，這得益於其領先的製藥和生物技術公司、世界一流的學術研究機構以及強大的創業投資生態系統的協同效應。此外，支持性的法規結構，尤其是美國藥物管理局（FDA），對人工智慧驅動的藥物開發工具日益開放，正在促進市場發展。該地區先進的醫療基礎設施和高昂的醫療成本進一步促進了尖端人工智慧技術的採用，鞏固了其在人工智慧老年保護劑研發領域的領先地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率。這得益於生物技術和製藥產業的顯著擴張、政府推動醫療保健領域人工智慧創新的舉措增多，以及日本和中國等國家人口老化的快速發展。此外，老齡化疾病的盛行率不斷上升，迫切需要有效的治療性介入。增加對人工智慧新興企業，以及在本地和全球參與者之間建立策略夥伴關係關係，是推動該地區市場加速擴張的關鍵因素。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球人工智慧抗衰老產品開發市場（按治療領域）

  • 老年人和與老齡化相關的虛弱
  • 心血管疾病
  • 神經退化性疾病
  • 代謝疾病
  • 腫瘤學
  • 其他與老齡化相關的治療領域

6. 全球人工智慧老年保護器創建市場（按技術）

  • 機器學習（ML）
    • 監督學習
    • 無監督學習
    • 強化學習
    • 深度學習（DL）
  • 人工智慧世代
    • 自然語言處理（NLP）
    • 電腦視覺
    • 其他生成式人工智慧
  • 基於圖的人工智慧和知識圖譜

第7章全球人工智慧老年保護器創建市場（按應用）

  • 目標識別與檢驗
  • 潛在客戶開發和最佳化
  • 藥物再利用
  • 生物標記的發現與老化手錶
  • 毒性和安全性預測
  • 臨床前試驗

第 8 章全球人工智慧老年保護器創建市場（按最終用戶）

  • 製藥和生物技術公司
  • 合約研究組織（CRO）
  • 學術和研究機構
  • 長壽Start-Ups和診所

9. 全球人工智慧老年保護器創建市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要發展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Insilico Medicine
  • Deep Longevity
  • Juvenescence
  • BioAge Labs
  • Calico
  • Recursion Pharmaceuticals
  • BenevolentAI
  • Xaira Therapeutics
  • Arda Therapeutics
  • InVivo Biosystems
  • Gero
  • Helix
  • Valo Health
  • Exscientia
  • Atomwise
  • BERG
Product Code: SMRC30494

According to Stratistics MRC, the Global AI Geroprotector Discovery Market is accounted for $316 million in 2025 and is expected to reach $1628 million by 2032 growing at a CAGR of 26.4% during the forecast period. AI Geroprotector Discovery refers to the application of artificial intelligence and machine learning to identify, screen, and optimize compounds or interventions that can slow, prevent, or reverse aging-related processes. By analyzing vast biological datasets, AI enables faster prediction of geroprotective potential, reduces trial-and-error in drug development, and accelerates precision targeting of aging mechanisms.

Market Dynamics:

Driver:

Rising global aging population

The escalating global geriatric demographic is a primary driver for the AI geroprotector discovery market. This population cohort exhibits a heightened prevalence of age-related disorders, thereby amplifying the demand for innovative therapeutic interventions that target the biological mechanisms of aging. Additionally, this demographic shift imposes a significant strain on healthcare systems, creating an urgent need for efficacious and preventative anti-aging solutions. Consequently, the rising aging population directly fuels investment and research into AI-driven discovery of geroprotectors, which promise to extend healthspan and mitigate the economic burden associated with age-related morbidity.

Restraint:

High initial capital investment for technology infrastructure

The development and application of AI algorithms for drug discovery necessitate access to high-performance computing (HPC) systems, vast data storage solutions, and specialized software, all of which entail exorbitant costs. The recruitment of a highly skilled workforce comprising data scientists, computational biologists, and AI specialists further escalates operational expenditures. This high financial barrier effectively consolidates market presence among well-funded established players and constrains the participation of small and medium-sized enterprises (SMEs), potentially stifling innovation.

Opportunity:

Development of personalized geroprotective regimens

AI algorithms can be leveraged to analyze multi-omics data, lifestyle factors, and clinical histories to identify patient-specific aging biomarkers and predict individual responses to potential geroprotectors. This capability facilitates the development of highly tailored therapeutic regimens that maximize efficacy and minimize adverse effects. Furthermore, this personalized approach allows for the stratification of patient populations in clinical trials, enhancing trial design and accelerating the path to regulatory approval for novel, targeted anti-aging compounds.

Threat:

The "Black Box" problem and interpretability of AI predictions

When AI systems generate a potential geroprotector candidate without providing clear, interpretable insights into the underlying biological rationale, it creates significant hurdles. Regulatory bodies like the FDA and EMA require a comprehensive understanding of a drug's mechanism of action for approval. This opacity can erode trust among clinicians and researchers, potentially delaying clinical translation and limiting the widespread integration of AI-derived discoveries into mainstream therapeutic development pipelines.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the AI geroprotector discovery market. Initially, it disrupted research activities and supply chains, causing temporary delays in non-COVID-related projects. However, it subsequently acted as a significant accelerator by underscoring the critical role of advanced computational approaches in rapid drug discovery and repurposing. The pandemic highlighted the vulnerabilities of the elderly population to novel pathogens, thereby reinforcing the importance of research into healthspan extension. This led to increased investor interest and funding directed towards AI-powered biotechnology platforms, ultimately netting a positive long-term effect on market growth.

The machine learning (ML) segment is expected to be the largest during the forecast period

The machine learning (ML) segment is expected to account for the largest market share during the forecast period due to its unparalleled proficiency in identifying complex, non-linear patterns within vast biological datasets. ML algorithms, particularly deep learning networks, are exceptionally adept at processing high-throughput screening data, genomic sequences, and proteomic profiles to predict the geroprotective efficacy and toxicity of novel molecules. Their ability to continuously learn and improve from new data makes them indispensable for target identification, lead optimization, and biomarker discovery. This versatility and proven effectiveness in other drug discovery domains solidify ML's position as the largest segment.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, driven by the profound intersection between aging and carcinogenesis. Aging is a primary risk factor for cancer, as the accumulation of cellular damage and senescence creates a permissive environment for tumorigenesis. Many geroprotectors, such as senolytics, exhibit strong anti-cancer potential by selectively eliminating premalignant senescent cells. The high incidence of cancer within the aging population presents a clear clinical pathway and a substantial addressable market for AI-discovered therapies that can simultaneously target fundamental aging processes and oncogenesis, which is fueling the segment growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, attributed to its synergistic confluence of leading pharmaceutical and biotechnology companies, world-class academic research institutions, and a robust venture capital ecosystem. Moreover, the presence of a supportive regulatory framework, particularly from the U.S. FDA, which is increasingly open to AI-derived drug development tools, facilitates market growth. The region's advanced healthcare infrastructure and high healthcare expenditure further enable the adoption of cutting-edge AI technologies, consolidating its position as the frontrunner in the AI geroprotector discovery landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by a significant expansion in its biotechnology and pharmaceutical sectors, increasing government initiatives aimed at fostering AI innovation in healthcare, and a rapidly aging population in countries like Japan and China. Additionally, the rising prevalence of age-related diseases is creating an urgent need for effective gerotherapeutic interventions. The growing investment in AI startups and the establishment of strategic partnerships between regional and global players are key factors catalyzing the market's accelerated expansion in this region.

Key players in the market

Some of the key players in AI Geroprotector Discovery Market include Insilico Medicine, Deep Longevity, Juvenescence, BioAge Labs, Calico, Recursion Pharmaceuticals, BenevolentAI, Xaira Therapeutics, Arda Therapeutics, InVivo Biosystems, Gero, Helix, Valo Health, Exscientia, Atomwise and BERG.

Key Developments:

In June 2025, BioAge has launched an initiative to analyze over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets targeting the biology of aging. This molecular profiling is expected to expand insights and identify novel therapeutic targets for aging-related diseases.

In April 2024, AI-based drug developer Xaira Therapeutics has been launched with more than $1 billion in capital and a self-described ambitious commitment to transform drug discovery and development by creating new and more effective treatments faster.

Therapeutic Areas Covered:

  • Cardiovascular Diseases
  • Neurodegenerative Diseases
  • Metabolic Diseases
  • Oncology
  • Other Age-related Therapeutic Areas

Technologies Covered:

  • Machine Learning (ML)
  • Generative AI
  • Graph-Based AI & Knowledge Graphs

Applications Covered:

  • Target Identification & Validation
  • Lead Generation & Optimization
  • Drug Repurposing
  • Biomarker Discovery & Aging Clocks
  • Toxicity & Safety Prediction
  • Preclinical Testing

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutions
  • Longevity-focused Startups & Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AI Geroprotector Discovery Market, By Therapeutic Area

  • 5.1 Introduction
  • 5.2 Geriatric Diseases & Age-related Frailty
  • 5.3 Cardiovascular Diseases
  • 5.4 Neurodegenerative Diseases
  • 5.5 Metabolic Diseases
  • 5.6 Oncology
  • 5.7 Other Age-related Therapeutic Areas

6 Global AI Geroprotector Discovery Market, By Technology

  • 6.1 Introduction
  • 6.2 Machine Learning (ML)
    • 6.2.1 Supervised Learning
    • 6.2.2 Unsupervised Learning
    • 6.2.3 Reinforcement Learning
    • 6.2.4 Deep Learning (DL)
  • 6.3 Generative AI
    • 6.3.1 Natural Language Processing (NLP)
    • 6.3.2 Computer Vision
    • 6.3.3 Other Generative AI
  • 6.4 Graph-Based AI & Knowledge Graphs

7 Global AI Geroprotector Discovery Market, By Application

  • 7.1 Introduction
  • 7.2 Target Identification & Validation
  • 7.3 Lead Generation & Optimization
  • 7.4 Drug Repurposing
  • 7.5 Biomarker Discovery & Aging Clocks
  • 7.6 Toxicity & Safety Prediction
  • 7.7 Preclinical Testing

8 Global AI Geroprotector Discovery Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical and Biotechnology Companies
  • 8.3 Contract Research Organizations (CROs)
  • 8.4 Academic and Research Institutions
  • 8.5 Longevity-focused Startups & Clinics

9 Global AI Geroprotector Discovery Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Insilico Medicine
  • 11.2 Deep Longevity
  • 11.3 Juvenescence
  • 11.4 BioAge Labs
  • 11.5 Calico
  • 11.6 Recursion Pharmaceuticals
  • 11.7 BenevolentAI
  • 11.8 Xaira Therapeutics
  • 11.9 Arda Therapeutics
  • 11.10 InVivo Biosystems
  • 11.11 Gero
  • 11.12 Helix
  • 11.13 Valo Health
  • 11.14 Exscientia
  • 11.15 Atomwise
  • 11.16 BERG

List of Tables

  • Table 1 Global AI Geroprotector Discovery Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AI Geroprotector Discovery Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 3 Global AI Geroprotector Discovery Market Outlook, By Geriatric Diseases & Age-related Frailty (2024-2032) ($MN)
  • Table 4 Global AI Geroprotector Discovery Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 5 Global AI Geroprotector Discovery Market Outlook, By Neurodegenerative Diseases (2024-2032) ($MN)
  • Table 6 Global AI Geroprotector Discovery Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 7 Global AI Geroprotector Discovery Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 8 Global AI Geroprotector Discovery Market Outlook, By Other Age-related Therapeutic Areas (2024-2032) ($MN)
  • Table 9 Global AI Geroprotector Discovery Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global AI Geroprotector Discovery Market Outlook, By Machine Learning (ML) (2024-2032) ($MN)
  • Table 11 Global AI Geroprotector Discovery Market Outlook, By Supervised Learning (2024-2032) ($MN)
  • Table 12 Global AI Geroprotector Discovery Market Outlook, By Unsupervised Learning (2024-2032) ($MN)
  • Table 13 Global AI Geroprotector Discovery Market Outlook, By Reinforcement Learning (2024-2032) ($MN)
  • Table 14 Global AI Geroprotector Discovery Market Outlook, By Deep Learning (DL) (2024-2032) ($MN)
  • Table 15 Global AI Geroprotector Discovery Market Outlook, By Generative AI (2024-2032) ($MN)
  • Table 16 Global AI Geroprotector Discovery Market Outlook, By Natural Language Processing (NLP) (2024-2032) ($MN)
  • Table 17 Global AI Geroprotector Discovery Market Outlook, By Computer Vision (2024-2032) ($MN)
  • Table 18 Global AI Geroprotector Discovery Market Outlook, By Other Generative AI (2024-2032) ($MN)
  • Table 19 Global AI Geroprotector Discovery Market Outlook, By Graph-Based AI & Knowledge Graphs (2024-2032) ($MN)
  • Table 20 Global AI Geroprotector Discovery Market Outlook, By Application (2024-2032) ($MN)
  • Table 21 Global AI Geroprotector Discovery Market Outlook, By Target Identification & Validation (2024-2032) ($MN)
  • Table 22 Global AI Geroprotector Discovery Market Outlook, By Lead Generation & Optimization (2024-2032) ($MN)
  • Table 23 Global AI Geroprotector Discovery Market Outlook, By Drug Repurposing (2024-2032) ($MN)
  • Table 24 Global AI Geroprotector Discovery Market Outlook, By Biomarker Discovery & Aging Clocks (2024-2032) ($MN)
  • Table 25 Global AI Geroprotector Discovery Market Outlook, By Toxicity & Safety Prediction (2024-2032) ($MN)
  • Table 26 Global AI Geroprotector Discovery Market Outlook, By Preclinical Testing (2024-2032) ($MN)
  • Table 27 Global AI Geroprotector Discovery Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global AI Geroprotector Discovery Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 29 Global AI Geroprotector Discovery Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 30 Global AI Geroprotector Discovery Market Outlook, By Academic and Research Institutions (2024-2032) ($MN)
  • Table 31 Global AI Geroprotector Discovery Market Outlook, By Longevity-focused Startups & Clinics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.